In the company’s news yesterday,
Peregrine Pharmaceuticals announced that the U.S. Patent and Trademark Office issued U.S. Patent Number No. 7,455,833 to the company. This patent includes broad claims covering anti-viral applications of antibodies that directly bind to aminophospholipids. According to the press release, the aminophospholipid family of phospholipids represents a novel target for anti-viral therapies.
Steven W. King, president and CEO of Peregrine, commented, “Issuance of this broad anti-viral patent significantly expands our intellectual property leadership the field of phospholipid-targeting antibodies. Antibodies falling under the scope of this new patent are already showing promise in preclinical studies of lethal virus diseases including hemorrhagic fever and AIDS.”
Dr. Shelley Fussey, vice president of intellectual property at Peregrine, added, “We believe this is a significant patent in the anti-viral field and we are especially pleased at the scope of the issued claims, which reflect the broad anti-viral potential of our phospholipid-targeting antibody platform. This patent further extends the breadth of our intellectual property for our anti-PS technology platform, while nicely complementing the intellectual property estate we have developed for our lead clinical stage anti-PS antibody bavituximab, which binds to PS through a different mechanism.”
Yesterday’s news follows the publication of a study in Nature Medicine that supports the broad anti-viral potential of the company’s anti-phospholipid platform. The study showed that phospholipid-targeting drugs can cure lethal virus infections in animal disease models. The publication is the latest in a series of external validations of the company’s anti-viral program.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.
To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
